Bronchial Leiomyoma Companies

ID: MRFR/Pharma/3418-HCR

90 Pages

Rahul Gotadki

October 2025

Bronchial leiomyomas are rare tumors that arise from smooth muscle cells in the bronchi of the lungs. While information specific to companies exclusively focused on bronchial leiomyomas may be limited due to the rarity of the condition, medical institutions, oncology-focused companies, and research organizations may be involved in the diagnosis and treatment of such tumors.

Bronchial Leiomyoma Market Research Report – Global Forecast till 2035 Infographic

Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Bronchial Leiomyoma Market

Bronchial leiomyomas Market

Latest Bronchial Leiomyoma Companies Updates:

Cook Medical Received FDA approval for its PASSCO catheter, a specialized balloon dilatation device used for airway stenting, which could potentially be applied to manage symptoms caused by bronchial leiomyomas.

Siemens Healthineers Introduced the SOMATOM Force multi-detector CT scanner with AI-powered image reconstruction, potentially improving lung disease diagnosis, including bronchial leiomyomas.

Medtronic Continues to develop its portfolio of minimally invasive surgical instruments and energy devices, which could be relevant for future bronchial leiomyoma treatment options.

List of Bronchial Leiomyoma Key companies in the market:

Hoffmann-La Roche Ltd (Europe)

AstraZeneca (Europe)

Eli Lilly and Company. (U.S.)

Sanofi (Europe)

Pfizer Inc. (U.S.)

GlaxoSmithKline Plc. (U.S.)

ArQule. (U.S.)

Boehringer Ingelheim GmbH (Europe)